Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.

A Pilot Randomized Controlled Study on the Effects of an Educational Training Program on Skin Reactions Induced by Chemotherapies, Epidermal Growth Factor Inhibitors (EGFRI) Treatments, and Immunotherapies.

Outcome
Finished, no results posted
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
1 January 2019
Ended
10 August 2022
Enrollment
40 participants
Sites
1
Primary outcomes
Skin grades
Sponsor type
Academic / other
Results posted
No
Last update
13 February 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The main adverse reaction of EGFR seen in patients is rash. EGFR treated patients have a 24-95% incidence of rash depending on the type of treatment they receive. Skin toxicity may occur in more than 80% of patients treated with cetuximab. If a severe rash (Grade 3 or 4) occurs, a dose reduction or discontinuation of treatment may be required. Also, infections are the main secondary side effect caused by the rash. The aim of the study is through a randomized clinical trial feasibility study to investigate the effectiveness of an educational intervention in patients receiving EGFRI therapy. It will be randomly selected which patients will belong to the intervention group and who in the control group. The type of program involves educational intervention.

Detailed description public domain (ClinicalTrials.gov)

In recent years, EGFRI (Epidermal Growth Factor Receptor Inhibitor) have evolved as effective anti-cancer drugs. They are distinguished in monoclonal antibodies (cetuximab and panitumumab) and EGFR (TKIs) kinase inhibitors gefitinib, erlotinib and lapatinib, where they are used in the treatment of colon, rectal, head and neck, lung, pancreas and of breast. According to studies, the usual treatment for the prevention and treatment of skin rash refers to the use of antibiotics such as doxycycline, tetracycline and cortisone products such as hydrocortisone. It is also recommended to use moisturizing cream. The study of Carmine P. et al., 2011 mentions the need to investigate educational measures for the rash due to EGFR treatment.

Intervention public domain (ClinicalTrials.gov)

Other: Educational training program. The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects. The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks.

Arm public domain (ClinicalTrials.gov)

Experimental (experimental): The patients in the experimental group follow the educational program once weekly, for 4 weeks.

Arm public domain (ClinicalTrials.gov)

NON-INTERVENTION (no intervention): The usual information was provided to them

Primary outcome public domain (ClinicalTrials.gov)

Skin grades. Repeated measurements were taken weekly regarding the grade of rash, pruritus and photosensitivity. Time frame: 4 weeks.

Secondary outcome public domain (ClinicalTrials.gov)

Functional health and wellbeing status. Time frame: 4 weeks.

Eligibility public domain (ClinicalTrials.gov)

1. Adult cancer patients (\>18). 2. Patients who suffered with pruritus, or rash or photosensitivity, in the onset of the symptoms. 3. Willing to participate. 4. Ability to complete the questionnaires. 5. A performance status of two or less on the Eastern Cooperative Oncology Group (ECOG). 6. Patients with no pre-existing dermatological condition that may limit the interpretation of results.

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 40 participants (actual).